Título Abreviado: ECM 22/1845
Investigador Principal: María Díez Campelo
Código EUDRACT:
Código Identificativo: ECI2022/0155

CA055-026

A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Estado: ACTIVO

Pin It en Pinterest